Regulation of stanniocalcin-1 (STC-1) secretion by BeWo cells and first trimester human placental tissue from normal pregnancies and those at increased risk of developing preeclampsia

Running title: Secretion of Stanniocalcin-1 by human trophoblasts.

Abid N1\*, Embola J1\*, Tryfonos Z1\*, Bercher J1, Ashton SV, Khalil A1,2, Thilaganathan B1,2, Cartwright JE1$, Whitley GS1$#.

1Centre for Vascular Biology, Molecular and Clinical Sciences Research Institute, St George’s, University of London, Cranmer Terrace, London SW17 0RE.

2 Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, UK

\*These authors contributed equally

$These authors contributed equally

#To whom correspondence should be addressed.

Corresponding authors: Guy S Whitley and Judith E Cartwright

Centre for Vascular Biology, Molecular and Clinical Sciences Research Institute, St George’s, University of London, Cranmer Terrace, London SW17 0RE

E.mail: gwhitley@sgul.ac.uk Tel: +44 (0)20 8725 5781

E.mail: jcartwri@sgul.ac.uk Tel: +44 (0)20 8725 0803

**Non-standard abbreviations**

BSA Bovine serum albumin

cAMP Adenosine- 3', 5'- cyclic monophosphate

8 Br-cAMP 8-Bromo adenosine- 3', 5'- cyclic monophosphate

DAB 3,3’-diaminobenzidine

DP44mT di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone

Epac Exchange proteins directly activated by cAMP

FCS Fetal Calf Serum

GSK-3β Glycogen Synthase Kinase-3β

hCG Human Chorionic gonadotrophin

HIF Hypoxia Inducible factor

HRE Hypoxia response element

IGF Insulin like growth factor

IGFBP4 Insulin like growth factor binding protein

mTOR mammalian target of rapamycin

mTORC mammalian target of rapamycin complex

NDRG-1 N-Myc Downstream-Regulated Gene 1

NHS National Health Service

PAPP-A Pregnancy-Associated Plasma Protein-A

PI3-Kinase Phosphatidylinositol-3 kinase

PBS Phosphate buffered saline

PBST Phosphate buffered saline with tween

PKA Protein Kinase A

SGK-1 Serum and glucocorticoid induced kinase-1

STC-1 Stanniocalcin-1

TBS Tris buffered saline

TBST Tris buffered saline with tween

**Abstract**

Stanniocalcin-1 (STC-1) is a multi-functional glycosylated peptide present in the plasma of healthy women postpartum and increased further in pregnancies complicated by preeclampsia. Although the *STC-1* gene is expressed by the placenta what regulates its secretion and from which cells at the feto-maternal interface is unknown. Here we demonstrate for the first time that the syncytiotrophoblast and cytotrophoblast are a major site of STC-1 protein expression in first trimester placental tissue. Further, in response to low oxygen, first trimester chorionic villous tissue from pregnancies at increased risk of developing preeclampsia secreted significantly more STC-1 than normal tissue under the same conditions. Using the human trophoblast cell line BeWo we have shown that low oxygen increased the secretion of STC-1 but it required co-stimulation with the Adenosine- 3', 5'- cyclic monophosphate (cAMP) analogue, 8-Bromo adenosine- 3', 5'- cyclic monophosphate cAMP (8 Br-cAMP) to reach significance. Inhibition of Hypoxia inducible factor 2α (HIF-2α) and the Phosphatidylinositol-3 kinase (PI3-Kinase)/AKT/ Serum and glucocorticoid induced kinase-1(SGK-1) pathway resulted in significant inhibition of STC-1 secretion. As both low oxygen and cAMP are known to play a central role in placental function, their regulation of STC-1 points to a potentially important role in the maintenance of a normal healthy pregnancy and we would hypothesise that it may act to protect against prolonged placental hypoxia seen in preeclampsia.

Key words;

Stanniocalcin-1, Trophoblasts, Placenta, Hypoxia, First trimester

**Introduction**

Stanniocalcin is a secreted glycoprotein first identified in bony fish where it acts to regulate calcium and phosphate homeostasis (1). Although the mammalian homologue stanniocalcin-1 (STC-1) may serve a similar function, a wider expression in both normal and pathological tissue would suggest other roles. Support for this in mammals comes from studies indicating different sub-cellular locations and the expression of different molecular forms (2). STC-1 has been implicated in a spectrum of biological processes including cell migration, apoptosis and oxidative phosphorylation. It has anti-inflammatory properties (3) and acts as a calcium channel blocker in the heart (4-7). STC-1 is present in the serum of healthy pregnant but not non-pregnant women and is further elevated in pregnancies complicated by preeclampsia (8). Although the expression of the gene is detected in placental tissue and peaks mid-gestation, the cellular origin was not reported (8). Collectively these results suggest that STC-1 not only has a role in maintaining a healthy pregnancy but may also play a part in the pathology of common pregnancy complications. However, whether it is playing a protective or pathological role has not been established.

One possible role for STC-1 is inhibiting the activity of pregnancy-associated plasma protein-A (PAPP-A), a proteolytic enzyme that cleaves the inhibitory binding protein IGFBP4 and prevents the release of active IGF-1(9). Circulating maternal IGF-1 acts to both reduce blood pressure and stimulate fetal growth (10). It has also been proposed that the effects of STC-1 on the kidney could account for the proteinuria and renal failure that can accompany preeclampsia (8, 11).

The aims of this study are three fold: 1) determine the cellular origin of STC-1 in the placenta, 2) investigate how the secretion of STC-1 is regulated and 3) determine whether first trimester placental tissue from the pregnancies at increased risk of developing preeclampsia secrete more STC-1 than tissue from low risk pregnancies.

**Materials and Methods**

The pharmacological modulators used in this study were obtained from the following manufacturers: 8- Bromo adenosine- 3', 5'- cyclic monophosphate ( 8-Br-cAMP ), sodium salt (Biolog, Germany), protein kinase A (PKA) inhibitor, N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinoline sulfonamide (H89), the Exchange proteins directly activated by cAMP (Epac) inhibitor, α-[(2-(3-Chlorophenyl)hydrazinylidene]-5-(1,1-dimethylethyl)-β-oxo-3-isoxazolepropanenitrile (ESI-09), the mTORC 1 and 2 inhibitor, KU0063794 and the SGK-1 inhibitor, GSK650394 (Tocris, Abingdon UK), PT2385 (AbCam Cambridge UK), the PI3-Kinase inhibitor LY294002 (Sellekchem, Absource Diagnostics, Germany), AKT inhibitor IV, and Rapamycin (Calbiochem, Watford UK), Desferrioximine and NDRG-1 activator, di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (DP44mT; Sigma Gillingham, UK).

**Doppler Ultrasound Scanning of first trimester Uterine Arteries**

Doppler ultrasound screening of uterine arteries was performed on women undergoing elective surgical termination of pregnancy at St George’s University Hospital, NHS Foundation Trust. Inclusion criteria included singleton pregnancy, gestational age 8-14 weeks, normal fetal anatomy and nuchal translucency thickness, and no known maternal medical condition or history of recurrent miscarriage. The gestational age was calculated by crown-rump length measurement. Doppler ultrasound was performed by a trained sonographer as described previously (12). Following a study of 10,000 ongoing pregnancies, we have established reference ranges of the resistance indices (13). In this study, a high- resistance index (RI) is defined as a pregnancy with bilateral uterine artery notches and a mean RI≥95th centile; while a normal-RI presents no uterine artery notches and a mean RI<95th centile. The risk of developing preeclampsia would be five times greater in the high-RI group had the pregnancy gone to term.

**Serum samples obtained during the third trimester**

The patients were recruited from the antenatal clinics and the inpatient wards at St George’s Hospital. There was no significant difference in gestational age between the normotensive and pre-eclamptic pregnancies. The diagnosis of preeclampsia was made according to the criteria of the International Society for the Study of Hypertension in Pregnancy(14). The exclusion criteria included major fetal abnormalities and those ending in termination, miscarriage or fetal death before 24 weeks. Data on maternal baseline demographics and pregnancy outcomes were collected from the hospital maternity records.

**Immunohistochemistry**

Paraffin-embedded placental tissue sections (7 µm) were cut and mounted on slides and immersed in xylene, twice for 5 mins. The slides were then re-hydrated using a series of ethanol dilutions from 100% to 70% (v/v) and then washed in water for 5 mins. Heat inactivating epitope retrieval of STC-1 and cytokeratin-7 (CK-7) was performed using 11 mM tri-sodium citrate, pH 6.0 containing 0.05% (v/v) Tween20 or 10 mM Tris buffer pH 10, for the CK-7 respectively.

Sections were washed twice with Tris buffered saline pH 10 [(TBS) containing 140 mM NaCl, 2.68 mM KCL, 16.7 mM Trisma base] and permeabilised using TBS with 0.2% Triton X-100 (v/v) for 5 min. Sections were washed twice and non-specific binding blocked using TBS containing 1% (w/v) bovine serum albumin (BSA), or 10% (v/v) goat serum for one hour at room temperature (RT). Sections were then incubated with a polyclonal mouse anti-human STC-1 antibody (1µg/ml) (SantaCruz, California, USA) or polyclonal mouse anti-human CK-7 antibody [0.621 µg/ml) (Dako, Glostrup Municipality, Denmark) in TBS containing 1% (v/v) BSA, 0.025% Triton X-100 (v/v in a humidified chamber overnight. Non-immune IgG of equal concentrations from the same species were used as negative controls.

After an overnight incubation sections were washed with TBS and endogenous peroxidase activity blocked with 0.3% H202 (v/v) in TBS. Sections were then incubated with Histostain broad spectrum biotin/streptavidin system (Invitrogen, Waltham, Massachusetts, USA) following the manufacturer’s protocol, washed twice in TBS before being incubated with 2-Solution (3,3’-diaminobenzidine) DAB kit (Roche, Basel, Switzerland). Sections were counter stained using Harris Haematoxylin solution and the nuclei blued using saturated lithium carbonate solution. Images were taken using an Olympus IX70 microscope with an attached XC10 camera (Olympus, Tokyo, Japan) using CellSens Dimensions software (Olympus).

**Immunocytochemistry**

Cells were grown on gelatine coated glass coverslips under the appropriate conditions and then washed twice in PBS before fixing with ice –cold methanol for 10 mins. The cells were then washed twice for 5 mins with PBS and incubated in PBS/0.2% (v/v) Tween 20. After 10 mins the cells were washed twice for 5 mins with PBS and blocked with 10% (v/v) goat serum in PBS for 20 mins at room temperature. The fixed and blocked cells underwent three further 5 min washes in PBS and were incubated with either the primary antibody (Anti-STC1 MAB2958 5µg/ml; R&D Systems) or isotype-matched immunoglobulin control (IgG2βκ, ebioscince) for 1 h at room temperature. Cells were then washed three times in PBS for 5 min and incubated in the secondary antibody (anti-mouse biotinylated IgG; Vector Labs) for 45 min at room temperature. Following, three washes with PBS for 5 min, cells were incubated with streptavidin-fluorescein (3.3µg/ml, Vector Labs) for 30 min in the dark, at room temperature. All antibodies were diluted in PBS/1.5% (v/v) GS and 0.2% (v/v) Tween-20. Cells were washed three times with PBS and 1-2 drops of DAPI-containing Vectashield® (Vector Labs) was added. Images were captured using a Nikon A1R Confocal Microscope and imported into ImageJ. Each image was adjusted using the Brightness and Contrast tool using the identical parameters and saved as .PNG.

**Cell Culture**

The choriocarcinoma derived cytotrophoblast cell line (BeWo) used in this study (Pattillo et al., 1968) were maintained in Dulbecco’s Modified Eagle’s Medium (with 4500 mg/L glucose, sodium pyruvate and sodium bicarbonate, Sigma) and Ham’s F12 medium (1:1) supplemented with 10% (v/v) Fetal Calf Serum (FCS), penicillin (100IU/ml), streptomycin (100 µg/ml) and L-glutamine (2mmol/L).

**Stimulating cells for Enzyme Linked Immunosorbent Assay (ELISA) analysis**

BeWo cells were seeded at a density of 4-5x105 cells per well of a 6 well plate in 1.5 ml of the DMEM/HAM’s F-12 containing 10% (v/v) FCS. The cells were incubated overnight to allow them to settle and then incubated according to the experiments with 100μM 8Br-cAMP, pharmacological inhibitors (GSK650394 at both 100 μM and 10 μM, LY294002 at 50 μM and 10μM, AKT inhibitor IV at 2.5 μM, 5 μM KU0063794 at 1 μM, Rapamycin at 10 ng/ml) and also stimulators (DP44mT at 25 μM and 10 μM). To assess the effect of reduced oxygen, cells were placed inside sealed blood bags (Baldwin Medical Supplies, Knoxville, VIC, Australia) flushed with 1% oxygen (O2) with 5% CO2 in N2 at 37°C as previously described (15). Otherwise cells were incubated at 5% CO2 in air at 37°C in a humidified incubator. All the cells were incubated for 48 hours at 37°C.

**Determination of STC-1 in the culture medium**

After incubation the cell culture medium was collected, centrifuged at 14,000 g for 5 mins and the resulting supernatant separated from the pellet. The volume of the supernatant was determined. STC-1 in the culture supernatant was determined by enzyme linked immunosorbent assay (ELISA) as per the manufacturer’s instructions (DuoSet R&D Systems). The cells were washed once with PBS and lysed, the protein concentration was determined using the Bradford protein assay. The amount STC-1 produced was then expressed per mg of total cellular protein.

**Stimulating cells for western blot analysis**

BeWo cells were seeded at a density of 6x106 cells per 10cm dish in culture media and left to adhere overnight. The cells were then incubated with the appropriate inhibitor for 20 min before the addition of 8Br-cAMP (100μM). Cells were either incubated at 21% O2, or 1% O2, in 5% CO2 and air. All cells were incubated for up to 48 hours at 37°C.

**Western blot analysis for cells and tissue**

After incubation the cells were lysed in up to 200 μl of RIPA buffer containing 100 mM sodium orthovanadate, 17 mg/ml aprotinin, phosphoSTOP (Roche) and 10 mg/ml phenylmethylsulonylfluoride), sonicated and centrifuged at 14,000 g for 5 mins and the supernatant collected. Placental tissue (5-10mg) was homogenised in 1ml of RIPA buffer using a FastPrep-24 homogenisation tube containing Lysis Matrix D. Protein concentrations were determined using the Bradford protein assay. Approximately 30-50 μg of protein per well was resolved on a polyacrylamide gel before transfer to Immobilon-FL transfer membrane (Millipore, UK). Protein loading and transfer efficiency was followed using tubulin. Non-specific reactivity was then blocked Tris-buffered saline (TBS) with 5% (w/v) low fat milk powder for 1 h at room temperature. Blots were probed with the following antibodies: HIF1α (Cell signalling, 1:1000), HIF2α (Novis, NB100-122 1:750) and Tubulin (Sigma 1:10,000) in 5% (w/v) BSA in TBS containing 01% (v/v) Tween 20.

The blots were then washed in TBST and incubated with goat anti-rabbit IgG conjugated to horseradish peroxidase (1:10000; A5420, Sigma, UK) for 1h at room temperature, and antigen-antibody complexes were detected using an enhanced chemiluminescence system (Amersham Biosciences UK). Blots were subsequently stripped in buffer containing 62.5 mM Tris pH 6.7, 2% (w/v) SDS and 100 mM β-mercaptoethanol and probed with a rabbit polyclonal antibody to human β-actin or mouse monoclonal antibody to human anti-Tubulin (1:10000; Ab7291, Abcam UK). Where indicated, western blots were scanned and the integrated intensity of each band determined using ImageJ (http://rsbweb.nih.gov/ij/docs/intro.html). Results were expressed as a ratio to loading control within the same sample.

**Transfection of BeWo cells with siRNA**

Cells were cultured in HAM’s-F12 medium containing 10% (v/v) FCS without antibiotics for 48 h prior to transfection by Nucleofection (Amaxa Biosystems, Germany). Following trypsinsation 2x106 cells were resuspended in 100 µl of cell line solution L with either 300nM of control siRNA-A (Santa Cruz sc-37007) or targeted si-RNA EPAS-1 (Santa Cruz sc-35316) and transfected following the manufacturers' instructions using programs X-005 as previously detailed (16). Following transfection, cells were seeded at approximately 5×105/well of a 6 well plate in HAM’s-F12 medium containing 10% (v/v) FCS without antibiotics. After 24 h the medium was replaced with DMEM/HAM’s F-12 containing 10% (v/v) FCS and incubated for 48 h in 1% O2 with and without 100µM 8Br-cAMP.

**Ethics**

Subjects involved in this study gave informed written consent and the study protocols had either local Wandsworth Ethics Committee (ref: 01.96.8, 01.78.5) or the London-Stanmore Research Ethics Committee (ref: 12/LO/0810) approval.

**Statistical Analysis**

Graph Pad Prism 5.0 (Graph Pad Software Inc., San Diego, CA, USA) was used for statistical analysis. At least three independent experiments were performed and the results expressed as mean + standard error of the mean. Where appropriate a D'Agostino & Pearson normality test was performed followed by a one-way ANOVA with Holm-Sidak's multiple comparisons test. A p value of <0.05 was considered to be statistically significant.

**Results**

**Expression of STC-1 in placental tissue and BeWo cells**

Immunohistochemical staining of adjacent sections of first-trimester chorionic tissue demonstrated co-incident expression of CK-7 and STC-1 in both the syncytium and underlying cytotrophoblasts (Figure 1). Some staining in the placental endothelial cells and stromal cells was observed. Immunocytochemical analysis of BeWo cells stimulated with 100µM 8Br-cAMP and incubated in 1% O2 for 48 h indicated largely cytoplasmic staining for STC-1 (Figure 1).

**Serum STC-1 in normal pregnancy and pregnancies complicated by preeclampsia**

The circulating serum concentration of STC-1 at term in healthy pregnant women and women with preeclampsia was determined by ELISA. The concentration of STC-1 in normal pregnancy was 11.36 ng/ml ± 4.8 sem (n=19) and 63.71± 34.5 sem ng/ml (n=12) for those pregnancies complicated by preeclampsia, p<0.05 (Figure 2a).

**Secretion of STC-1 by placental tissue**

Freshly isolated first trimester placental tissue from normal-RI and high-RI pregnancies were incubated for 24h at 1% O2. They were then transferred to fresh medium and cultured for a further 72 h. There was significantly more STC-1 secreted from the tissue from the high-RI pregnancies compared to the normal-RI placental tissue (p<0.01; n>12 experiments as determined by ELISA; Figure 2b).There was no significant difference in the secretion of STC-1 between the two groups when tissue was cultured at 21% O2.

**The effect of 8Br-cAMP and low O2 on the secretion of STC1 by the trophoblast cell line BeWo**

The membrane permeable cAMP analogue, 8Br-cAMP, promotes formation of syncytial structures and the secretion of Human chorionic gonadotrophin (hCG) by BeWo cells (17). We therefore examined the effect of cAMP on the secretion of STC-1 in these cells. At 21% O2 the effect of 8Br-cAMP on the secretion of STC-1 by BeWo cells did not reach statistical significance. Culturing cells in 1% O2 in combination with 8Br-cAMP lead to an increase in the secretion of STC-1 compared to 21% O2 that reached significance at 100 µM with a 9 fold increase (p<0.001). The highest dose of 500 µM resulted in a 19 fold increase (p<0.0001). This data indicates that both cAMP and O2 regulated pathways act synergistically to stimulate STC-1 secretion in BeWo cells (Figure 3a). It was also possible to mimic the effect of reducing the oxygen concentration by treating the cells with the iron chelator desferrioximine, which, at 21% O2 lead to a three-fold increase in the secretion of STC-1 over 8Br-cAMP alone and a significant increase compared to control (p<0.05; Figure 3b).

**Role of O2 regulated pathways in STC-1 secretion**

Oxygen regulates cellular activity in a number of ways including through the increased stabilisation of HIF. Western blot analysis demonstrated the expression of both HIF-1 and 2α in BeWo cells cultured for 48 h in 1% O2 (Figure 3c and 3d). To determine which factor was involved in the regulation of STC-1 we used a HIF-2α specific antagonist, PT2385 (18). Incubation of BeWo cells with 1 µM PT2385 significantly inhibited the secretion of STC-1 in response to 1% O2/100 µM 8Br-cAMP (Figure 3e). We confirmed the involvement of HIF-2α using RNA-mediated interference. Following transfection with non-targeting control si-RNA there was a significant increase in the secretion of STC-1 following the culture of BeWo cells 48 h in 1% O2 and 100µm cAMP. However following transfection with HIF-2α siRNA inhibited 1% O2 and 100µm cAMP stimulated STC-1 completely (Figure 3f).

**Investigation of cAMP dependent pathways**

Having established a role for cAMP in the secretion of STC-1, we investigated downstream targets of cAMP, PKA and Epac. BeWo cells were treated with inhibitors of PKA, H-89 (10µM), and the inhibitor of Epac, ESI-09 (50µM and 100µM) and then stimulated with 1% O2/100 µM 8Br-cAMP and incubated for 48 hours. Inhibition of PKA with H89 had a small, but significant effect on STC-1 secretion (p<0.05, n=6; Figure 4a) however inhibition of Epac had no effect (data not shown).

**Role of the PI3-Kinase/AKT pathway in the secretion of STC-1 by BeWo**

There is evidence to suggest that the PI3-Kinase/Akt pathway can be activated in response to elevated cAMP (19). To determine whether activation of the PI3-Kinase/Akt pathway is involved in regulating the secretion of STC-1 by trophoblasts we used the pharmacological modulator Ly294002. Ly294002 inhibited the secretion of STC-1 in a dose dependent manner, reaching statistical significance at 10µM (p<0.05; Figure 4b). Inhibiting the activation of AKT with AKT inhibitor IV also significantly inhibited the secretion of STC-1 in response to 8Br-cAMP/1% O2 to below the levels of 1% O2 alone (p<0.01; Figure 4c).

**Role of mammalian target of rapamycin (mTOR) in the secretion of STC-1 by BeWo**

Mammalian target of rapamycin (mTOR) is associated with two complexes, mTOR complex (mTORC)-1 and -2, which act are both downstream and upstream of Akt respectively. To assess the role of mTOR in the secretion of STC-1 we used two inhibitors; rapamycin (RAP) which targets mTORC1 and KU-0063794 which inhibits both mTORC1 and 2. Only KU-0063794 (KU) had a significant effect on the secretion of STC-1 (p<0.01; Figure 4d).

**Role of SGK-1 in the secretion of STC-1 by BeWo**

The above data implicates mTORC2 in the mediation of cAMP/1% O2 stimulated STC-1 secretion. Activation of mTORC2 results in the activation of not only AKT but also a number of other pathways including SGK-1. Inhibition of SGK-1 with GSK 650394 significantly reduced the secretion of STC-1 in a dose dependent manner (10 µM p<0.05 n=6 experiments, 100 µM p<0.01; Figure 4e). Downstream targets of SGK-1 include N-Myc Downstream-Regulated Gene 1 (NDRG-1) and Glycogen Synthase Kinase-3β (GSK-3β). Using western blot analysis we were able to demonstrate an increase in the phosphorylation and therefore activation of NDRG-1 in response to cAMP/1% O2. However direct activation NDRG-1 following stimulation with Dp44mt had no effect on the secretion of STC-1 by BeWo cells (data not shown). Inhibition of HIF-2α with PT2385 had no effect on the phosphorylation of NDRG-1 (data not shown). To explore the possible involvement of the GSK-3β in this process we incubated BeWo cells with kenpaullone, a GSK-3β inhibitor which significantly (p<0.01) enhanced the secretion of STC-1 in response to cAMP/1% O2 (Figure 4f).

**Discussion**

The placenta is a pregnancy specific organ that develops rapidly throughout gestation. It acts as the crucial interface between the fetus and the mother. It has a number of functions but pertinent to this study is its role as a major endocrine organ, modulating and adapting the maternal response to pregnancy. We have focused on STC-1, a little studied hormone, which in health is only detectable in the circulation during pregnancy and is further elevated in pregnancies complicated by preeclampsia.

In the current study we established that the protein STC-1 was predominantly expressed in the syncytiotrophoblast and cytotrophoblast cells of first trimester placental tissue where it is co-localised with the expression of CK-7. Less intense expression was also seen in placental endothelial and stromal cells. We were further able to demonstrate a significant difference in the circulating concentration of STC-1 in the women with preeclampsia compared to normal pregnancies. These results were largely consistent with previously published data from plasma collected post-partum (8). In addition, we found that the secretion of STC-1 by first trimester chorionic villous explants cultured at 1% O2 was significantly greater in pregnancies at increased risk of developing preeclampsia. As the syncytium is the likely source of STC-1 found in the maternal circulation we examined the possible mechanisms that might regulate the secretion of STC-1 using first trimester placental tissue and the BeWo trophoblast cell line.

 Human chorionic gonadotrophin stimulates the differentiation of syncytiotrophoblast through the elevation of intracellular cAMP (20). We therefore determined whether cAMP could play a role in regulating STC-1 secretion using the membrane permeable phosphodiesterase resistant analogue, 8Br-cAMP. Although the effect of cAMP in regulating *STC-1* mRNA expression has been studied, the effect is tissue specific. In human endometrial stromal cells and rat neuroblastoma cells, cAMP stimulates STC-1 expression (21, 22). However in rat Sertoli and Leydig cells the opposite effect was observed (23). It has previously been reported that elevated intracellular cAMP induced cell fusion and differentiation in BeWo cells(24). In this study, 8Br-cAMP alone had no effect on the secretion of STC-1 by BeWo cells cultured in atmospheric oxygen suggesting that differentiation of BeWo cells alone was insufficient for secretion.

In early gestation the human fetus develops in a relatively low oxygen environment. Around the 10th week of pregnancy the delivery of blood to developing placenta changes significantly due to the remodelling of the maternal arteries and the loss of the trophoblast plugs (25). In pregnancies that later develop preeclampsia and/or fetal growth restriction this remodelling fails to occur adequately resulting in placental under-perfusion and intermittent hypoxia. We therefore hypothesised that one possible stimulus for the increased placental expression and secretion of STC-1 seen in pre-eclamptic pregnancies could be low oxygen. In support of this, low oxygen is associated with increased *STC-1* gene expression a number of pathological situations including cerebral ischemia (26) and carcinogenesis (27-29) and heart failure (5). Using a human tumour cell line, both low oxygen and the chemical induction of hypoxia, using either desferoxamine or cobalt chloride, also increased *STC-1* gene expression (30). Culturing BeWo cells in 1% O2 did not increase the secretion of STC-1. We therefore examined whether low oxygen in combination with increased intracellular cAMP could act to stimulate STC-1 secretion and found that there was a dose dependent increase in the secretion of STC-1 in response to 8Br-cAMP when cultured in low O2 which reached statistical significance at 100 µM 8Br-cAMP. There are at least two intracellular targets for cAMP in trophoblasts, PKA and Epac. Using inhibitors and activators of these targets we were able to establish that the majority of the stimulus for the secretion of STC-1 by BeWo cells was mediated by PKA which was in accord with earlier findings in the ovary (31).

Oxygen responsive genes are regulated by members of the HIF family of transcription factors. The best studied isoforms are HIF-1α and HIF-2α which share a number of structural and functional similarities but differ in expression patterns, target genes, and regulatory mechanisms. In low O2, HIF-1α and HIF-2α dimerise with HIF-1β forming HIF-1 and HIF-2 respectively. They then translocate to the nucleus where they regulate target gene expression by binding to and activating a hypoxia response element (HRE). Both HIF-1α and HIF-2α proteins are expressed in the human placenta. HIF-1α is widely distributed whereas the expression of HIF-2α is restricted largely to the trophoblasts (32, 33). A HRE has been identified in the promotor of STC-1 (34) and using the HIF-2α specific inhibitor PT2385 (18), which antagonises the binding of HIF-2α to HIF-1β, we were able to demonstrate that the secretion of STC-1 by BeWo cells was HIF-2α mediated. To investigate the effect of cAMP on the expression of HIF-2α we used western blot analysis. As predicted cells grown in low O2 expressedHIF-2α and stimulation of cells with 8Br-cAMP led to a significant increase in expression. PT2385 is a selective and potent small-molecule inhibitor of HIF-2α identified by a structure-based design approach. It allosterically binds to HIF-2α and blocks heterodimerization with HIF-1β (18). Crystallographic analysis of this interaction reveals no such binding of PT2385 to HIF-1α. Although this does not exclude off-target effects in the current study it does suggest the effects demonstrated are not mediated through the inhibition of HIF1-α. The importance of HIF-2α in regulating the secretion of STC-1 was confirmed using validated RNA-interference techniques targeting the expression of HIF-2α.

Using pharmacological inhibitors and activators we examined the interaction between HIF-2α and 8Br-cAMP further and have shown that inhibiting PI3-kinase/Akt pathway with Ly294002, and Akt-inhibitor IV in BeWo cells led to significant inhibition of cAMP/1%O2 induced STC-1 secretion. A similar interaction between the cAMP/PKA and PI3-Kinase/AKT pathway has been shown in endothelial cells where a cAMP mediated inhibition of Rho-kinase led to an increase PI3-Kinase activation (35, 36).

Studies in HUVEC and HeLa cells (37) support the view that both HIF-1α and HIF-2α are regulated by mTOR signalling. mTOR is associated with two mTOR complexes, (mTORC) 1 and 2, which act both downstream and upstream of Akt respectively (38). Although HIF-1α expression seems to be regulated by mTORC-1 and -2, HIF-2α expression was primarily dependent on mTORC2 (39, 40). To assess the role of mTOR in trophoblast secretion of STC-1 by 8Br-cAMP and 1% O2 we used rapamycin which targets mTORC1 and KU-0063794 which inhibits both mTORC-1 and 2. KU-0063794, but not rapamycin, significantly inhibited STC-1 secretion by trophoblasts indicating that mTORC-2 is primarily involved in the regulation of STC-1 secretion by BeWo cells.

 Activation of mTORC2 in turn activates a number of proteins including Akt, and SGK-1. In the present study as with Akt, inhibition of SGK-1 led to a dose dependent inhibition of STC-1 secretion. One of the targets of SGK-1 is NDRG-1. NDRG-1 expression has also been shown to be regulated by hypoxia through the activation of HIF-1α(41). We therefore examined the role of NDRG-1 on the secretion of STC-1 by BeWo cells. Stimulation of BeWo cells lead to a significant increase in the phosphorylation of NDRG-1 at both 1% and 21% O2 and this was not affected following inhibition of HIF-2α with PT2385. Direct activation of NDRG-1 by Dp44tm had no effect on STC-1 secretion. This suggests that although activated under these conditions, NDRG-1 played no role in the secretion of STC-1 by BeWo cells. Both Akt and SGK-1 are members of the same AGC subfamily of protein kinases and have similar substrate specificities. Both Akt and SGK-1 phosphorylate and inactivate GSK-3β. Inhibition of GSK-3β using kenpaullone resulted in an increase in STC-1 secretion further supporting a role for GSK-3β as a negative regulator. When active, GSK-3β is known to phosphorylate HIF-1α targeting it for proteasomal degradation (42-44).Whether GSK-3β has the same effect on HIF-2α has yet to be determined.

In conclusion we have shown that STC-1 is expressed by syncytial cytotrophoblasts, and is secreted in greater amounts by first trimester chorionic villous tissue under conditions of low oxygen. We have demonstrated that in low oxygen, the secretion of STC-1 by a human trophoblast cell line is increased by elevated intracellular cAMP. We have further shown that this response is mediated through the activation of the PI3-Kinase/Akt/SGK-1 pathway primarily through activation of mTORC-2 and involves the transcription factor HIF-2α. While some caution should always be taken when extrapolating in vitro results using cell lines to the in vivo situation, we were also able to demonstrate a similar result using chorionic villous explants which more closely model the in vivo situation. This, together with the localisation of STC-1 to the trophoblastic layers of the chorionic villi, points to a potentially important role for STC-1 in the maintenance of a normal healthy pregnancy.

Although the role of STC-1 in pregnancy is unclear it has positive effects on cardiac function including the inhibition of hypoxia-induced cardiomyocyte apoptosis and attenuation of ischemic cardiac injury. A therapeutic role in heart failure has also been proposed. Given increasing evidence that the maternal cardiovascular system is fundamentally involved in the aetiology of preeclampsia (45), we postulate that STC-1 might protect the maternal cardiovascular system from stress in normal pregnancy however its role in preeclampsia/FGR is less clear and warrants further study.

**Acknowledgements**

We would like to thank Dr Veronica Carroll for helpful discussions. The study was MRC [Co]-funded by Medical Research Council grant no. MR/M02184X/1. JE was funded on a Society of Reproduction and Fertility Summer Studentship and was a Biomedical Science BSC student of St Georges University of London. ZT was funded by the MRC. NA was an MRes student of St Georges University of London. JB was in part funded by the EU Erasmus programme. JEC, GW and SA are HEFCE funded. We would like to thank the medical staff of the Fetal Medicine Unit, St George's University Hospital, for help in patient recruitment. Figure 5 of this manuscript was prepared using the Motifolio drawing toolkit.

**Author Contribution**

The study was conceived and planned by GW and JC. The majority of the experimentation was performed by JE, NA, ZT, JB and SA. The recruitment of the patients for the study was overseen by BT and AK. The first draft of the paper was written by GW and JC. All authors contributed to the editing of the manuscript.

**References**

1. Chang, A. C., Janosi, J., Hulsbeek, M., de Jong, D., Jeffrey, K. J., Noble, J. R., and Reddel, R. R. (1995) A novel human cDNA highly homologous to the fish hormone stanniocalcin. *Mol Cell Endocrinol* **112**

2. Trindade, D. M., Silva, J. C., Navarro, M. S., Torriani, I. C., and Kobarg, J. (2009) Low-resolution structural studies of human Stanniocalcin-1. *BMC structural biology* **9**, 57

3. Mohammadipoor, A., Lee, R. H., Prockop, D. J., and Bartosh, T. J. (2016) Stanniocalcin-1 attenuates ischemic cardiac injury and response of differentiating monocytes/macrophages to inflammatory stimuli. *Translational research : the journal of laboratory and clinical medicine* **177**, 127-142

4. Ellard, J. P., McCudden, C. R., Tanega, C., James, K. A., Ratkovic, S., Staples, J. F., and Wagner, G. F. (2007) The respiratory effects of stanniocalcin-1 (STC-1) on intact mitochondria and cells: STC-1 uncouples oxidative phosphorylation and its actions are modulated by nucleotide triphosphates. *Mol Cell Endocrinol* **264**, 90-101

5. Sheikh-Hamad, D., Bick, R., Wu, G. Y., Christensen, B. M., Razeghi, P., Poindexter, B., Taegtmeyer, H., Wamsley, A., Padda, R., Entman, M., Nielsen, S., and Youker, K. (2003) Stanniocalcin-1 is a naturally occurring L-channel inhibitor in cardiomyocytes: relevance to human heart failure. *Am J Physiol Heart Circ Physiol* **285**, H442-448

6. Meidan, R., Klipper, E., Zalman, Y., and Yalu, R. (2013) The role of hypoxia-induced genes in ovarian angiogenesis. *Reprod Fertil Dev* **25**, 343-350

7. Chang, A. C., Doherty, J., Huschtscha, L. I., Redvers, R., Restall, C., Reddel, R. R., and Anderson, R. L. (2015) STC1 expression is associated with tumor growth and metastasis in breast cancer. *Clin Exp Metastasis* **32**, 15-27

8. Uuskula, L., Mannik, J., Rull, K., Minajeva, A., Koks, S., Vaas, P., Teesalu, P., Reimand, J., and Laan, M. (2012) Mid-gestational gene expression profile in placenta and link to pregnancy complications. *PLoS ONE* **7**, e49248

9. Kloverpris, S., Mikkelsen, J. H., Pedersen, J. H., Jepsen, M. R., Laursen, L. S., Petersen, S. V., and Oxvig, C. (2015) Stanniocalcin-1 Potently Inhibits the Proteolytic Activity of the Metalloproteinase Pregnancy-associated Plasma Protein-A. *J Biol Chem* **290**, 21915-21924

10. Maulik, D., Frances Evans, J., and Ragolia, L. (2006) Fetal growth restriction: pathogenic mechanisms. *Clin Obstet Gynecol* **49**, 219-227

11. Juhanson, P., Rull, K., Kikas, T., Laivuori, H., Vaas, P., Kajantie, E., Heinonen, S., and Laan, M. (2016) Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy: Clinical, Life-Style, and Genetic Modulators. *J Clin Endocrinol Metab* **101**, 4799-4807

12. Hollis, B., Mavrides, E., Campbell, S., Tekay, A., and Thilaganathan, B. (2001) Reproducibility and repeatability of transabdominal uterine artery Doppler velocimetry between 10 and 14 weeks of gestation. *Ultrasound Obstet Gynecol* **18**, 593-597

13. Leslie, K., Whitley, G. S., Herse, F., Dechend, R., Ashton, S. V., Laing, K., Thilaganathan, B., and Cartwright, J. E. (2015) Increased Apoptosis, Altered Oxygen Signaling, and Antioxidant Defenses in First-Trimester Pregnancies with High-Resistance Uterine Artery Blood Flow. *Am. J. Pathol.* **185**, 2731-2741

14. Brown, M. A., Lindheimer, M. D., de Swiet, M., Van Assche, A., and Moutquin, J. M. (2001) The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). *Hypertens Pregnancy* **20**, Ix-xiv

15. Wallace, A. E., Goulwara, S. S., Whitley, G. S., and Cartwright, J. E. (2014) Oxygen modulates human decidual natural killer cell surface receptor expression and interactions with trophoblasts. *Biol Reprod* **91**, 134

16. Forbes, K., Desforges, M., Garside, R., Aplin, J. D., and Westwood, M. (2009) Methods for siRNA-mediated reduction of mRNA and protein expression in human placental explants, isolated primary cells and cell lines. *Placenta* **30**, 124-129

17. Martinez, F., Kiriakidou, M., and Strauss, J. F., 3rd. (1997) Structural and functional changes in mitochondria associated with trophoblast differentiation: methods to isolate enriched preparations of syncytiotrophoblast mitochondria. *Endocrinology* **138**, 2172-2183

18. Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., Grina, J. A., Halfmann, M. M., Maddie, M. A., Olive, S. R., Schlachter, S. T., Tan, H., Wang, B., Wang, K., Xie, S., Xu, R., Yang, H., and Josey, J. A. (2016) A Small-Molecule Antagonist of HIF2alpha Is Efficacious in Preclinical Models of Renal Cell Carcinoma. *Cancer Res* **76**, 5491-5500

19. Garcia-Morales, V., Luaces-Regueira, M., and Campos-Toimil, M. (2017) The cAMP effectors PKA and Epac activate endothelial NO synthase through PI3K/Akt pathway in human endothelial cells. *Biochem Pharmacol* **145**, 94-101

20. Weedon-Fekjaer, M. S., and Tasken, K. (2012) Review: Spatiotemporal dynamics of hCG/cAMP signaling and regulation of placental function. *Placenta* **33 Suppl**, S87-91

21. Aghajanova, L., Altmae, S., Kasvandik, S., Salumets, A., Stavreus-Evers, A., and Giudice, L. C. (2016) Stanniocalcin-1 expression in normal human endometrium and dysregulation in endometriosis. *Fertil Steril* **106**, 681-691.e681

22. Wong, C. K., Yeung, H. Y., Mak, N. K., DiMattia, G. E., Chan, D. K., and Wagner, G. F. (2002) Effects of dibutyryl cAMP on stanniocalcin and stanniocalcin-related protein mRNA expression in neuroblastoma cells. *J Endocrinol* **173**, 199-209

23. Li, L., and Wong, C. K. (2008) Effects of dexamethasone and dibutyryl cAMP on stanniocalcin-1 mRNA expression in rat primary Sertoli and Leydig cells. *Mol Cell Endocrinol* **283**, 96-103

24. Wice, B., Menton, D., Geuze, H., and Schwartz, A. L. (1990) Modulators of cyclic AMP metabolism induce syncytiotrophoblast formation in vitro. *Exp Cell Res* **186**, 306-316

25. Burton, G. J., Woods, A. W., Jauniaux, E., and Kingdom, J. C. P. (2009) Rheological and Physiological Consequences of Conversion of the Maternal Spiral Arteries for Uteroplacental Blood Flow during Human Pregnancy. *Placenta* **30**, 473-482

26. Zhang, K., Lindsberg, P. J., Tatlisumak, T., Kaste, M., Olsen, H. S., and Andersson, L. C. (2000) Stanniocalcin: A molecular guard of neurons during cerebral ischemia. *Proc Natl Acad Sci U S A* **97**, 3637-3642

27. Chang, A. C., Jellinek, D. A., and Reddel, R. R. (2003) Mammalian stanniocalcins and cancer. *Endocr Relat Cancer* **10**

28. Liu, G., Yang, G., Chang, B., Mercado-Uribe, I., Huang, M., Zheng, J., Bast, R. C., Lin, S. H., and Liu, J. (2010) Stanniocalcin 1 and ovarian tumorigenesis. *J Natl Cancer Inst* **102**

29. Ma, X., Gu, L., Li, H., Gao, Y., Li, X., Shen, D., Gong, H., Li, S., Niu, S., Zhang, Y., Fan, Y., Huang, Q., Lyu, X., and Zhang, X. (2015) Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma. *Journal of translational medicine* **13**, 56

30. Yeung, H. Y., Lai, K. P., Chan, H. Y., Mak, N. K., Wagner, G. F., and Wong, C. K. (2005) Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. *Endocrinology* **146**, 4951-4960

31. Paciga, M., DiMattia, G. E., and Wagner, G. F. (2004) Regulation of luteal cell big stanniocalcin production and secretion. *Endocrinology* **145**, 4204-4212

32. Cindrova-Davies, T., van Patot, M. T., Gardner, L., Jauniaux, E., Burton, G. J., and Charnock-Jones, D. S. (2015) Energy status and HIF signalling in chorionic villi show no evidence of hypoxic stress during human early placental development. *Mol Hum Reprod* **21**, 296-308

33. Highet, A. R., Khoda, S. M., Buckberry, S., Leemaqz, S., Bianco-Miotto, T., Harrington, E., Ricciardelli, C., and Roberts, C. T. (2015) Hypoxia induced HIF-1/HIF-2 activity alters trophoblast transcriptional regulation and promotes invasion. *Eur J Cell Biol* **94**, 589-602

34. Law, A. Y., Ching, L. Y., Lai, K. P., and Wong, C. K. (2010) Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. *Mol Cell Endocrinol* **314**, 118-127

35. Sanada, S., Asanuma, H., Tsukamoto, O., Minamino, T., Node, K., Takashima, S., Fukushima, T., Ogai, A., Shinozaki, Y., Fujita, M., Hirata, A., Okuda, H., Shimokawa, H., Tomoike, H., Hori, M., and Kitakaze, M. (2004) Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. *Circ.* **110**, 51-57

36. Wolfrum, S., Dendorfer, A., Rikitake, Y., Stalker, T. J., Gong, Y., Scalia, R., Dominiak, P., and Liao, J. K. (2004) Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. *Arterioscler Thromb Vasc Biol* **24**, 1842-1847

37. Kim, Y. S., Ahn, K. H., Kim, S. Y., and Jeong, J. W. (2009) Okadaic acid promotes angiogenesis via activation of hypoxia-inducible factor-1. *Cancer Lett* **276**, 102-108

38. Kim, L. C., Cook, R. S., and Chen, J. (2016) mTORC1 and mTORC2 in cancer and the tumor microenvironment. *Oncogene* **36**, 2191

39. Toschi, A., Lee, E., Gadir, N., Ohh, M., and Foster, D. A. (2008) Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. *J Biol Chem* **283**, 34495-34499

40. Mohlin, S., Hamidian, A., von Stedingk, K., Bridges, E., Wigerup, C., Bexell, D., and Pahlman, S. (2015) PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma. *Cancer Res* **75**, 4617-4628

41. Salnikow, K., Davidson, T., Zhang, Q., Chen, L. C., Su, W., and Costa, M. (2003) The involvement of hypoxia-inducible transcription factor-1-dependent pathway in nickel carcinogenesis. *Cancer Res* **63**, 3524-3530

42. He, J., Qi, D., Wang, D. X., Deng, W., Ye, Y., Feng, L. H., Zhu, T., Zhao, Y., and Zhang, C. R. (2015) Insulin upregulates the expression of epithelial sodium channel in vitro and in a mouse model of acute lung injury: role of mTORC2/SGK1 pathway. *Exp Cell Res* **331**, 164-175

43. Schmidt, K. M., Hellerbrand, C., Ruemmele, P., Michalski, C. W., Kong, B., Kroemer, A., Hackl, C., Schlitt, H. J., Geissler, E. K., and Lang, S. A. (2017) Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models. *Oncotarget* **8**, 24491-24505

44. Flugel, D., Gorlach, A., Michiels, C., and Kietzmann, T. (2007) Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. *Mol Cell Biol* **27**, 3253-3265

45. Thilaganathan, B., and Kalafat, E. (2019) Cardiovascular System in Preeclampsia and Beyond. *Hypertension* **73**, 522-531

**Figure 1: Histological and cytochemical analysis of first trimester placental tissue sections and BeWo cells grown in culture.** Top Left: Treated with non-immune IgG negative control stained purple. Top Right: Treated with mouse monoclonal anti-CK-7 antibody, brown highlights positive expression of CK-7. Middle Left: Treated with non-immune IgG negative control, Middle Right: Treated with mouse anti-STC-1 antibody, brown highlights positive expression STC-1. The data is representative of results from 3 different patient samples performed on separate occasions. BeWo cells were grown 1% O2 and stimulated with 100µM 8Br-cAMP for 24h. Bottom Left: Treated with non-immune IgG negative control, Bottom Right: Treated with mouse anti-STC-1 antibody (Green) and the nuclei stained with Dapi (Blue).

**Figure 2: Concentration of STC-1 in serum obtained from pregnancies in the third trimester with known outcomes.** a) Serum was obtained from normal and pre-eclamptic pregnancies the third trimester. The concentration of STC-1 was determined by ELISA and the data log-transformed. The data shown is expressed as mean ± SEM of n=19 normal pregnancies and n=11 pre-eclamptic pregnancies. Significance was determined using an unpaired student-t test \*p<0.05. **Secretion of STC-1 by first trimester chorionic tissue from nRI and hRI pregnancies incubated at 1% and 21% O2.** b)First trimester chorionic villous tissue was incubated at either 1% or 21% O2 for 72 h. The medium was then collected and the tissue weighed. STC-1 was determined by ELISA and the amount produced was corrected for the weight of tissue. The number of pregnancies in each group were nRI 1% (n=14), hRI 1% (n=12), nRI 21% (n=13) hRI 21% (n=12). The data was tested for normality using the D'Agostino & Pearson normality test before analysis using a one-way ANOVA followed by a Holm-Sidak's multiple comparisons test, \*\*p<0.01.

**Figure 3: The effect of cAMP and oxygen on production of STC-1 by BeWo cells.** a) BeWo cells (3x105 per well) were incubated in either 1% or 21% oxygen with increasing concentration of 8Bromo-cAMP. The data was expressed as mean + sem, of n=4 independent expts. b) BeWo cells were cultured in 21% O2 and stimulated with 100µM 8 Bromo-cAMP in the presence and absence of 50µM DFO (n=4 independent expts). **The effect of the low oxygen and cAMP on the expression of HIF-1, and HIF-2α.** BeWo cells were cultured in 1% and 21% O2 in presence and absence of 100µM 8 Bromo-cAMP for 48 h and cell lysates were examined by western blot analysis. c) HIF-1α (n=4 independent expts) and d) HIF-2α (n=7 independent expts) were detected by chemiluminescence, using tubulin as the loading control. The effect of inhibiting HIF-2α on the secretion of STC-1 was determined using e) PT2385, (n=3 independent expts) or f) RNA interference, (n=4 independent expts) in the presence and absence of 100µM 8 Bromo-cAMP. Stimulation in all experiments was for 48 h. The concentration of STC-1 in the medium was determined by ELISA. Total cellular protein was determined by Bradford assay. The results are expressed as pg of STC-1/mg of protein. The level of significance was determined using either, a Student-t test or a one-way ANOVA and a Sidak's multiple comparisons test where appropriate, \* p<0.05, \*\*p<0.01, p<0.005(\*\*), p<0.0005 (\*\*\*), p<0.0001 (\*\*\*\*).

**Figure 4: The effect of the inhibiting PI3kinase, Akt and mTORC 1 and 2 on the secretion of STC-1 by BeWo cells**. BeWo cells were cultured in 1% O2 in 100 µM 8 Bromo-cAMP in the presence and absence of a) the PKA inhibitor H89 (10µM), b) the PI3kinase inhibitor Ly 294002 (LY) at 1µM, 5µM and 10µM (n=3) c) Akt inhibitor IV (2.5µM) or d) either the mTORC1 inhibitor rapamycin (RAP) or the mTORC1 and 2 inhibitor KU 0063794 (KU). e) 10µM (n=5) and 100µM (n=3) GSK650394 in 1% O2 or, f) 1µM Kenpaullone. After 48 h the medium was removed and the STC-1 secreted measured by ELISA. Total cellular protein was determined by Bradford assay. The results are expressed as pg of STC-1/mg of protein. All data was expressed as mean+sem. The level of significance was determined using a one-way ANOVA and a Sidak's multiple comparisons test, or an unpaired t-test\* p<0.5, \*\*p<0.01 and \*\*\*p<0.001.

**Figure 5: Summary of the pathway intermediates involved in the secretion STC-1 by BeWo cells.** Solid arrows indicate demonstrated connections, dashed arrows are connects based on the literature.